Douglas Watson
Psychiatric/Mental Health · New Albany, INNPI 1770211658
Payments from drug & device makers
Across 220 payments — averaging $21.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Teva Pharmaceuticals USA, Inc.$597
- Axsome Therapeutics, Inc.$504
- Vanda Pharmaceuticals Inc.$463
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$450
- Alkermes, Inc.$399
- plus $988 from 14 others
What the payments were for
- Food & beverage$4,803100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 54 | $1,413 |
| Teva Pharmaceuticals USA, Inc. | 22 | $597 |
| Axsome Therapeutics, Inc. | 15 | $504 |
| Vanda Pharmaceuticals Inc. | 18 | $463 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 34 | $450 |
| Alkermes, Inc. | 27 | $399 |
| Otsuka America Pharmaceutical, Inc. | 13 | $328 |
| Lundbeck LLC | 7 | $135 |
| Tris Pharma Inc | 7 | $128 |
| Idorsia Pharmaceuticals US Inc | 4 | $66 |
| Neurocrine Biosciences, Inc. | 3 | $54 |
| Johnson & Johnson | 3 | $49 |
| Indivior Inc. | 2 | $44 |
| Supernus Pharmaceuticals, Inc. | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| Eisai Inc. | 2 | $31 |
| Currax Pharmaceuticals LLC | 2 | $30 |
| Corium, LLC | 1 | $25 |
| Noven Therapeutics, LLC | 1 | $17 |
| Collegium Pharmaceutical, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,815 in reported general payments places this provider in the 90th percentile of 729 psychiatric/mental health providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 15 | $20,997 |
| AuvelityDextromethorphan Hbr/Bupropion | 18 | $18,884 |
| VyvanseLisdexamfetamine Dimesylate | 13 | $4,590 |
| Divalproex Sodium ErDivalproex Sodium | 11 | $851 |
| Clonazepam | 22 | $192 |
| Gabapentin | 14 | $104 |
| Buspirone Hcl | 13 | $82 |
| Lamotrigine | 15 | $75 |
| Mirtazapine | 12 | $47 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $1,413 | $20,99715 claims |
| Axsome Therapeutics, Inc.Auvelity | $504 | $18,88418 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $33 | $4,59013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 729 psychiatric/mental health providers in Indiana.
Other psychiatric/mental health in New Albany
- Anne HoskinsNew Albany$12K
- Brooke KempfTerre Haute$1.1M
- Gerald LewisMerrillville$336K
- Lauren LutzColumbus$320K
- Sonya RuedlingerIndianapolis$134K
- Trina GreenwaldMarion$107K
- Paul DuncanJeffersonville$46K
- Morgan StamperConnersville$42K
- Jennifer JimenezUnion Mills$37K
- Savannah MullinsClarksville$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.